Spectrum Pharmaceuticals

ASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 28, 2024
Rheumatoid arthritis, Learning, EPS, Risk, Telephone, Patient, Suppository, Sale, Acquisition, News, ASRT, Complaint, Adjustment, P.C, Spectrum, Spectrum Pharmaceuticals, FDA, Food, Cryptocurrency

Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Assertio have breached their fiduciary duties to the company.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • Then, on November 8, 2023, Assertio issued a press release announcing its financial results for its third quarter ("Q3") of 2023.

March 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ASRT

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, Court, NEXT, Telephone, COST, Sale, Risk, CLASS, Spectrum Pharmaceuticals, LLP, ASRT, Cryptocurrency

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.
  • Follow the link below to get more information and be contacted by a member of our team:
    ASRT investors may also contact Joseph E. Levi, Esq.
  • WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

ASSERTIO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Assertio Holdings, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024
Complaint, Acquisition, Court, Person, Spectrum, Telephone, FDA, News, Food, Sale, District court, Learning, Adjustment, Risk, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, EPS, P.C, Cryptocurrency

Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Assertio

Retrieved on: 
Friday, March 1, 2024
Acquisition, Court, Spectrum, FDA, News, Food, Advertising, Sale, Learning, Adjustment, Risk, Suppository, Spectrum Pharmaceuticals, LLP, EPS, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Assertio’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Maison Solutions, Assertio, Dada, and Cummins and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
Nexus, Complaint, Acquisition, Prospectus, Register, Spectrum, Dada, Marketing, FDA, News, Food, Sale, CMI, Form, Adjustment, Risk, Learning, IPO, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, ASRT, EPS, P.C, Audit

For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS

Key Points: 
  • For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS
    Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Cummins class action go to: https://bespc.com/cases/CMI

Contact The Gross Law Firm by March 5, 2024 Deadline to Join Class Action Against Assertio Holdings, Inc. (ASRT)

Retrieved on: 
Wednesday, February 28, 2024
Acquisition, NEXT, Fraud, Sale, Risk, Spectrum Pharmaceuticals, ASRT, Inc., Security (finance)

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Assertio Holdings, Inc.

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Assertio Holdings, Inc.
    Shareholders who purchased shares of ASRT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • DEADLINE: March 5, 2024 Shareholders should not delay in registering for this class action.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

ASSERTIO HOLDINGS, INC. (NASDAQ: ASRT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Assertio Holdings, Inc.

Retrieved on: 
Monday, February 26, 2024
Acquisition, Court, Action Replay, Spectrum, News, Advertising, Sale, Complaint, District court, Risk, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, ASRT, Defendant, Security (finance)

If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.

Key Points: 
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 5, 2024.
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) Shareholders

Retrieved on: 
Monday, February 26, 2024
Acquisition, Court, NEXT, Telephone, COST, Sale, Risk, CLASS, Spectrum Pharmaceuticals, LLP, ASRT, Cryptocurrency

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Assertio Holdings, Inc. ("Assertio Holdings" or the "Company") (NASDAQ: ASRT) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Assertio Holdings investors who were adversely affected by alleged securities fraud between March 29, 2023 and November 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    ASRT investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Maison Solutions, Assertio, Dada, and Cummins and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 26, 2024
Nexus, Complaint, Acquisition, Prospectus, Register, Spectrum, Dada, Marketing, FDA, News, Food, Sale, CMI, Form, Adjustment, Risk, Learning, IPO, Suppository, Rheumatoid arthritis, Spectrum Pharmaceuticals, Patient, ASRT, EPS, P.C, Audit

For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS

Key Points: 
  • For more information on the Maison Solutions class action go to: https://bespc.com/cases/MSS
    Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • One of the Company's primary pharmaceutical products is Indocin, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Cummins class action go to: https://bespc.com/cases/CMI

ASSERTIO SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Assertio To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
Acquisition, Court, Spectrum, FDA, News, Food, Advertising, Sale, Learning, Adjustment, Risk, Woman, Suppository, Spectrum Pharmaceuticals, LLP, EPS, Cryptocurrency

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) and reminds investors of the March 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $25,000 investing in Assertio stock or options between March 9, 2023 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. ("Spectrum"), a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum's injection asset Rolvedon (the "Spectrum Acquisition").
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Assertio’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.